HK1257026A1 - 液體藥物組合物 - Google Patents

液體藥物組合物

Info

Publication number: HK1257026A1
Authority: HK; Hong Kong
Prior art keywords: pharmaceutical composition; liquid pharmaceutical; liquid; composition; pharmaceutical
Prior art date: 2014-05-23

Application number

HK18116149.6A

Other languages

English (en)

Inventor

G‧里納爾迪

S‧弗拉塔坎傑里

里奧 A‧德爾

Original Assignee

費森尤斯卡比德國有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-23

Filing date

2018-12-17

Publication date

2019-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1257026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-12-17 Application filed by 費森尤斯卡比德國有限公司 filed Critical 費森尤斯卡比德國有限公司

2019-10-11 Publication of HK1257026A1 publication Critical patent/HK1257026A1/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK18116149.6A 2014-05-23 2018-12-17 液體藥物組合物 HK1257026A1 (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14169754.0A EP2946766B1 (en)	2014-05-23	2014-05-23	Liquid pharmaceutical composition

Publications (1)

Publication Number	Publication Date
HK1257026A1 true HK1257026A1 (zh)	2019-10-11

Family

ID=50774705

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18116149.6A HK1257026A1 (zh)	2014-05-23	2018-12-17	液體藥物組合物

Country Status (21)

Country	Link
US (5)	US10493152B2 (zh)
EP (5)	EP2946766B1 (zh)
JP (3)	JP2017516847A (zh)
CN (2)	CN108785670A (zh)
AU (4)	AU2015263246B2 (zh)
CA (2)	CA2947487C (zh)
CY (1)	CY1120488T1 (zh)
DE (1)	DE23189888T1 (zh)
DK (3)	DK3148510T3 (zh)
ES (4)	ES2572919T3 (zh)
HK (1)	HK1257026A1 (zh)
HR (1)	HRP20181226T1 (zh)
HU (1)	HUE040097T2 (zh)
IL (1)	IL249117B2 (zh)
LT (1)	LT3148510T (zh)
PL (1)	PL3148510T3 (zh)
PT (1)	PT3148510T (zh)
RS (1)	RS57772B1 (zh)
SI (1)	SI3148510T1 (zh)
SM (1)	SMT201800413T1 (zh)
WO (1)	WO2015177058A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2946765T1 (sl)	2014-05-23	2016-11-30	Ares Trading S.A.	Tekoči farmacevtski sestavek
ES2572919T3 (es) *	2014-05-23	2016-06-03	Ares Trading S.A.	Composición farmacéutica líquida
ES2607489T3 (es)	2014-05-23	2017-03-31	Ares Trading S.A.	Composición farmacéutica líquida
ES2938608T3 (es) *	2017-09-20	2023-04-13	Tillotts Pharma Ag	Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
MX2020010030A (es) *	2018-03-29	2021-01-15	Airway Therapeutics Inc	Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
WO2020138517A1 (ko) *	2018-12-24	2020-07-02	삼성바이오에피스 주식회사	항-TNFα 항체를 포함하는 약제학적 조성물
AU2020207124A1 (en) *	2019-01-11	2021-07-29	Samsung Bioepis Co., Ltd.	Pharmaceutical composition comprising antibody, device comprising same, and use thereof
US20230203147A1 (en) *	2019-03-18	2023-06-29	Alvotech Hf	Aqueous formulations of tnf-alpha antibodies in high concentrations
CN115429751B (zh) *	2022-09-21	2023-11-17	景泽生物医药(合肥)股份有限公司	一种人重组卵泡刺激素注射剂及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6388197A (ja) *	1986-09-30	1988-04-19	Tosoh Corp	モノクロナル抗体の安定化方法
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
NZ536216A (en)	1996-02-09	2006-08-31	Abbott Biotech Ltd	Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US5900404A (en)	1997-08-15	1999-05-04	Amgen Inc.	Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en)	2002-08-16	2004-02-19	Hans-Juergen Krause	Formulation of human antibodies for treating TNF-alpha associated disorders
DK2335725T3 (en)	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
WO2005072772A1 (en)	2004-01-30	2005-08-11	Suomen Punainen Risti Veripalvelu	Pharmaceutical compositions
WO2006012500A2 (en) *	2004-07-23	2006-02-02	Genentech, Inc.	Crystallization of antibodies or fragments thereof
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
MX2007010971A (es)	2005-03-08	2007-09-19	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpo anti-citla-4.
RS52861B (en)	2005-06-07	2013-12-31	Esbatech - A Novartis Company Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF (ALPHA)
AU2008334099B2 (en)	2007-11-30	2014-07-24	Abbvie Biotechnology Ltd.	Protein formulations and methods of making same
US8080518B2 (en)	2007-12-05	2011-12-20	Arbor Vita Corporation	Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP3011953A1 (en)	2008-10-29	2016-04-27	Ablynx N.V.	Stabilised formulations of single domain antigen binding molecules
JP2012509270A (ja)	2008-11-17	2012-04-19	ジェネンテック，インコーポレイテッド	生理的条件下での高分子の凝集を低減するための方法及び製剤
SG10201401995UA (en)	2009-05-04	2014-08-28	Abbvie Biotechnology Ltd	Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9795674B2 (en) *	2010-02-26	2017-10-24	Novo Nordisk A/S	Stable antibody containing compositions
JP5937523B2 (ja)	2010-03-01	2016-06-22	サイトダインインコーポレイテッドＣｙｔｏＤｙｎ，Ｉｎｃ．	濃縮されたタンパク質製剤およびその使用
US20110223208A1 (en)	2010-03-09	2011-09-15	Beth Hill	Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN103124564B (zh)	2010-03-22	2016-11-09	弗·哈夫曼-拉罗切有限公司	对于稳定含有蛋白质的制剂有用的组合物和方法
EP2399604A1 (en)	2010-06-25	2011-12-28	F. Hoffmann-La Roche AG	Novel antibody formulation
WO2012065072A2 (en)	2010-11-11	2012-05-18	Abbott Biotechnology Ltd.	IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
EP2471554A1 (en)	2010-12-28	2012-07-04	Hexal AG	Pharmaceutical formulation comprising a biopharmaceutical drug
BR112013033671B1 (pt)	2011-07-01	2022-10-18	Biogen Ma Inc	Composições de polipeptídeo de fusão fc livre de arginina e uso
GB201112429D0 (en)	2011-07-19	2011-08-31	Glaxo Group Ltd	Antigen-binding proteins with increased FcRn binding
EP3412310B1 (en) *	2012-03-07	2022-09-07	Cadila Healthcare Limited	Pharmaceutical formulations of tnf-alpha antibodies
EP2863951A1 (en) *	2012-06-12	2015-04-29	Boehringer Ingelheim International GmbH	Pharmaceutical formulation for a therapeutic antibody
MX2015003007A (es)	2012-09-07	2015-06-05	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab.
KR20150070384A (ko)	2012-10-25	2015-06-24	메디뮨 엘엘씨	안정한 저점도 항체 제제
EP2727602A1 (en)	2012-10-31	2014-05-07	Takeda GmbH	Method for preparation of a high concentration liquid formulation of an antibody
EP2914289B1 (en)	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CA2889488A1 (en)	2012-11-01	2014-05-08	Abbvie Inc.	Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh)	2013-12-16	2019-04-16	浙江海正药业股份有限公司	一种含有阿达木单抗的药物组合物
IN2014MU00610A (zh)	2014-02-21	2015-09-25	Tata Motors Ltd
US10688187B2 (en)	2014-04-02	2020-06-23	Intas Pharmaceuticals Ltd.	Liquid pharmaceutical composition of adalimumab
ES2572919T3 (es) *	2014-05-23	2016-06-03	Ares Trading S.A.	Composición farmacéutica líquida
SI2946765T1 (sl)	2014-05-23	2016-11-30	Ares Trading S.A.	Tekoči farmacevtski sestavek
ES2607489T3 (es)	2014-05-23	2017-03-31	Ares Trading S.A.	Composición farmacéutica líquida
US11285210B2 (en) *	2016-02-03	2022-03-29	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
EP3569224B1 (en)	2017-01-11	2022-12-14	Celltrion Inc.	Stable liquid formula
US20230115267A1 (en)	2020-03-13	2023-04-13	Samsung Bioepis Co., Ltd.	Pharmaceutical liquid composition having increased stability

2014
- 2014-05-23 ES ES14169754.0T patent/ES2572919T3/es active Active
- 2014-05-23 EP EP14169754.0A patent/EP2946766B1/en not_active Not-in-force
2015
- 2015-05-15 US US15/313,480 patent/US10493152B2/en active Active
- 2015-05-15 SM SM20180413T patent/SMT201800413T1/it unknown
- 2015-05-15 ES ES19215036T patent/ES2955316T3/es active Active
- 2015-05-15 EP EP18169979.4A patent/EP3403646B1/en active Active
- 2015-05-15 DE DE23189888.3T patent/DE23189888T1/de active Pending
- 2015-05-15 AU AU2015263246A patent/AU2015263246B2/en not_active Revoked
- 2015-05-15 WO PCT/EP2015/060817 patent/WO2015177058A1/en active Application Filing
- 2015-05-15 IL IL249117A patent/IL249117B2/en unknown
- 2015-05-15 PT PT157249749T patent/PT3148510T/pt unknown
- 2015-05-15 CN CN201810768437.8A patent/CN108785670A/zh active Pending
- 2015-05-15 EP EP19215036.5A patent/EP3659582B1/en active Active
- 2015-05-15 LT LTEP15724974.9T patent/LT3148510T/lt unknown
- 2015-05-15 CA CA2947487A patent/CA2947487C/en active Active
- 2015-05-15 DK DK15724974.9T patent/DK3148510T3/en active
- 2015-05-15 CA CA3050875A patent/CA3050875A1/en not_active Abandoned
- 2015-05-15 EP EP23189888.3A patent/EP4249060A3/en active Pending
- 2015-05-15 RS RS20180919A patent/RS57772B1/sr unknown
- 2015-05-15 PL PL15724974T patent/PL3148510T3/pl unknown
- 2015-05-15 EP EP15724974.9A patent/EP3148510B1/en not_active Revoked
- 2015-05-15 HU HUE15724974A patent/HUE040097T2/hu unknown
- 2015-05-15 ES ES15724974.9T patent/ES2683194T3/es active Active
- 2015-05-15 CN CN201580039868.5A patent/CN106659781A/zh active Pending
- 2015-05-15 SI SI201530341T patent/SI3148510T1/sl unknown
- 2015-05-15 JP JP2017513323A patent/JP2017516847A/ja not_active Withdrawn
- 2015-05-15 ES ES18169979T patent/ES2928738T3/es active Active
2018
- 2018-08-01 HR HRP20181226TT patent/HRP20181226T1/hr unknown
- 2018-08-06 CY CY20181100812T patent/CY1120488T1/el unknown
- 2018-08-27 AU AU2018222887A patent/AU2018222887B2/en active Active
- 2018-09-07 DK DKBA201800070U patent/DK201800070Y8/da active IP Right Grant
- 2018-09-07 DK DKBA201800071U patent/DK201800071Y4/da active IP Right Grant
- 2018-12-17 HK HK18116149.6A patent/HK1257026A1/zh unknown
2019
- 2019-10-10 JP JP2019187090A patent/JP6962984B2/ja active Active
- 2019-11-25 US US16/694,627 patent/US10772961B2/en active Active
2020
- 2020-02-14 AU AU2020201090A patent/AU2020201090B2/en active Active
- 2020-08-11 US US16/990,954 patent/US11752208B2/en active Active
2021
- 2021-10-12 JP JP2021167297A patent/JP2022003091A/ja active Pending
2022
- 2022-06-03 AU AU2022203863A patent/AU2022203863A1/en not_active Abandoned
- 2022-11-02 US US17/979,272 patent/US11752209B2/en active Active
- 2022-11-02 US US17/979,309 patent/US12109267B2/en active Active

Also Published As

Publication number	Publication date
US20200085948A1 (en)	2020-03-19
EP2946766A1 (en)	2015-11-25
AU2018222887B2 (en)	2020-02-27
ES2955316T3 (es)	2023-11-30
US10772961B2 (en)	2020-09-15
AU2022203863A1 (en)	2022-06-23
EP3148510B1 (en)	2018-06-27
JP6962984B2 (ja)	2021-11-05
DE23189888T1 (de)	2024-03-21
AU2015263246A1 (en)	2016-11-17
SMT201800413T1 (it)	2018-11-09
EP2946766B1 (en)	2016-03-02
EP3403646B1 (en)	2022-09-28
US11752209B2 (en)	2023-09-12
ES2683194T3 (es)	2018-09-25
AU2018222887A1 (en)	2018-09-13
SI3148510T1 (sl)	2018-10-30
US12109267B2 (en)	2024-10-08
PT3148510T (pt)	2018-09-28
DK201800071Y4 (da)	2018-12-13
CN106659781A (zh)	2017-05-10
US20170189527A1 (en)	2017-07-06
EP3659582B1 (en)	2023-08-16
CY1120488T1 (el)	2019-07-10
DK201800071U1 (da)	2018-12-05
EP3148510A1 (en)	2017-04-05
IL249117B2 (en)	2024-11-01
US10493152B2 (en)	2019-12-03
EP3659582A1 (en)	2020-06-03
CA2947487C (en)	2019-09-24
EP3403646A1 (en)	2018-11-21
IL249117A0 (en)	2017-01-31
ES2928738T3 (es)	2022-11-22
ES2572919T3 (es)	2016-06-03
US20230061801A1 (en)	2023-03-02
WO2015177058A1 (en)	2015-11-26
DK201800070Y8 (da)	2019-07-09
LT3148510T (lt)	2018-10-10
PL3148510T3 (pl)	2018-11-30
EP4249060A2 (en)	2023-09-27
JP2020033361A (ja)	2020-03-05
DK3148510T3 (en)	2018-07-16
JP2017516847A (ja)	2017-06-22
US20210023215A1 (en)	2021-01-28
HUE040097T2 (hu)	2019-02-28
AU2020201090B2 (en)	2022-03-10
DK201800070Y4 (da)	2018-12-13
EP4249060A3 (en)	2024-01-03
AU2015263246B2 (en)	2018-06-21
JP2022003091A (ja)	2022-01-11
US11752208B2 (en)	2023-09-12
DK201800070U1 (da)	2018-09-18
RS57772B1 (sr)	2018-12-31
US20230338527A1 (en)	2023-10-26
HRP20181226T1 (hr)	2018-10-19
AU2020201090A1 (en)	2020-03-05
CA3050875A1 (en)	2015-11-26
CA2947487A1 (en)	2015-11-26
CN108785670A (zh)	2018-11-13
IL249117B1 (en)	2024-07-01

Publication	Publication Date	Title
IL282481A (en)	2021-06-30	A liquid pharmaceutical preparation
ZA201901590B (en)	2020-10-28	Liquid pharmaceutical composition
IL277241A (en)	2020-10-29	A liquid pharmaceutical preparation
ZA201901736B (en)	2020-11-25	Liquid pharmaceutical composition
HK1257026A1 (zh)	2019-10-11	液體藥物組合物
SG11201605366QA (en)	2016-08-30	Pharmaceutical composition containing pyridylaminoacetic acidcompound
AU2014386903B2 (en)	2020-01-30	Liquid pharmaceutical composition
PL3206666T3 (pl)	2020-09-21	Ciekła kompozycja farmaceutyczna zawierająca pemetreksed
HK1244685A1 (zh)	2018-08-17	液體藥物組合物
IL253572A0 (en)	2017-09-28	A liquid pharmaceutical preparation